Among HER family, the expression of EGFR, HER2 and HER3 have been observed in a substantial percentage of type II endometrial cancer patients and generally correlates with a shorter disease-free survival [205,206,207,208,209,210,211]. This evidence concerns the gene ERBB2 and endometrial cancer.